IL6 and metabolic dysfunction-associated steatotic liver disease: Furthermore, naringenin reduced hepatic lipid accumulation by significantly reducing the mRNA expression levels of monocyte chemotactic protein-1 (MCP1/Ccl2) and interleukin-6 (IL-6/II-6), leading to reduced hepatic lipid accumulation and decreased metabolic disorders associated with ovariectomy in female mice, including NAFLD [52].